Teva and Lonza Announce Strategic Partnership
23-Jan-2009
- Israel
The joint venture is expected to commence activities during the first quarter of 2009, subject to receipt of any applicable regulatory approvals. Financial details of this agreement are not being disclosed.
The companies will continue to assess their cooperation under the joint venture as both Teva and Lonza retain the ability to explore additional opportunities in the area of biosimilars beyond the scope of this partnership.
Organizations
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
Last viewed contents
Cellectis receives the 2009 INPI National Innovation Award
Go to page
Agilent teams with Battelle Memorial Institute to develop artificial neural network technology for protein research with LC/MS
Go to page
Roche to launch publicly accessible databases for clinical trials - Enhanced transparency through electronic databases for clinical trial protocol registration and reporting of results
Go to page
VCU EXPERTS IDENTIFY KEY MOLECULAR PLAYERS INVOLVED IN THE PATHOGENESIS OF LYME DISEASE
Go to page
Clayton, Dubilier & Rice Completes Acquisition of VWR International for $1.65 Billion - VWR International will continue to distribute Merck laboratory products
Go to page
Global Market for DNA Oligos Tops $700 Million Annually
Go to page
Milestone Strategic Agreement to Commercialise Australian Biotech Innovation
Go to page
Small code change, big effect - Using synthetic biology to precisely label proteins
Go to page
Researchers at Orion Genomics and Washington University Collaborate to Uncover DNA's "Second Code"
Go to page